Osel Sees Immunotherapy-Like Trajectory For Oncology Microbiome Candidate
Executive Summary
Depending on financing, the company could start a Phase III trial of CBM588 as early as this year, but it’s looking to develop the microbiome therapeutic for a potentially broad array of cancers.
You may also be interested in...
Early Success For 4D Pharma’s Microbiome Plus Keytruda Combination
After years of halting progress in its microbiome-based pipeline, 4D Pharma has produced promising early data from its cancer immunotherapy combination.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants
The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.